Article
Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Dec 2017
Dilokthornsakul Piyameth, Patidar Mausam, Campbell Jonathan D
Abstract excerpt
OBJECTIVES: To forecast lifetime outcomes and cost of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis (CF) with homozygous phe508del mutation from the US payer perspective. METHODS: A lifetime Markov model was developed from a US payer perspective. The model included five health states: 1) mild lung disease (percent predicted forced expiratory volume in 1 second [FEV1] >70%), 2) moderate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.